KR840000230A - 브롬헥신 서방출성 제형의 제조방법 - Google Patents
브롬헥신 서방출성 제형의 제조방법 Download PDFInfo
- Publication number
- KR840000230A KR840000230A KR1019820003017A KR820003017A KR840000230A KR 840000230 A KR840000230 A KR 840000230A KR 1019820003017 A KR1019820003017 A KR 1019820003017A KR 820003017 A KR820003017 A KR 820003017A KR 840000230 A KR840000230 A KR 840000230A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- weight
- spherical particles
- tablets
- methacrylic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 10
- 239000000203 mixture Substances 0.000 title claims 4
- 238000009472 formulation Methods 0.000 title claims 2
- 238000013268 sustained release Methods 0.000 title claims 2
- 239000012730 sustained-release form Substances 0.000 title claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims 11
- 239000012798 spherical particle Substances 0.000 claims 9
- 230000002378 acidificating effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 2
- ISSUNVDQFLJNRZ-UHFFFAOYSA-N CCCCCC.[Br] Chemical compound CCCCCC.[Br] ISSUNVDQFLJNRZ-UHFFFAOYSA-N 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 claims 1
- 229960003870 bromhexine Drugs 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007334 copolymerization reaction Methods 0.000 claims 1
- QSAWQNUELGIYBC-UHFFFAOYSA-N cyclohexane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCC1C(O)=O QSAWQNUELGIYBC-UHFFFAOYSA-N 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004911 serous fluid Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
도면 1은 브롬헥신 용액과 서방출성 브롬헥신 레트를 경구 투여한후 시간에 따른 혈장농도를 나타낸다.
Claims (10)
- 브롬헥신 및/또는 그의 염을 산 또는 산성물질과 함께 접착제의 존재하에서 산 또는 산성물질로 구성된 개시핵이나 중성의 개시핵에 적용시켜 구형 입자를 제조한 다음 제피를 형성하는 랙크용액을 구형입자에 분무하거나, 브롬헥신 및/또는 그의 염을 산성물질과 함께 과립화한 다음 압축 타정하여 정제를 제조하고 정제를 랙크로 제피시킴(여기에서 두가지 모두의 경우 랙크는, 산에 불용이고 장액에 가용인 랙크 50 내지 100중량 %와 위액 및 장액에 불용인 아크릴산 에스테르 및 메타크릴산 에스테르의 공중합에 0 내지 50중량%로 구성되어 있거나, 산에 불용이고 장액에 가용인 랙크 86 내지 100중량%와 에틸셀루로즈 0내지 14중량%로 구성되어 있으며, 구형의 입자 또는 정제의 중량에 대해 제피는 2내지 30중량%, 바람직하게는 3내지 20중량 %이다)을 특징으로 하여 제피물질로 제피된 구형입자 또는 정제로 구성되어 있는 브롬헥신의 서방출성 제형을 제조하는 방법.
- 제1항에 있어서, 브롬헥신 염기 또는 브롬헥신염 1몰당 75몰까지의 산 또는 산성물질을 사용함이 특징인 방법.
- 제1항 또는 제2항에 있어서, 활성물질의 총 용량이 5내지 100mg의 브롬헥신 또는 브롬헥산염임이 특징인 방법.
- 제1항 내지 제3항중의 어느 하나에 있어서, 구형입자가 둥근 과립의 형태이거나 펠레트 형태이며 직경이 0.1 내지 3mm임의 특징인 방법.
- 제1항 내지 제3항중의 어느 하나에 있어서, 장액에 가용인 랙크가 메타크릴산/메티크릴산 에스테르 공중합체(산가 180 내지 200), 히드록시-프로필메틸셀루로즈 프탈레이트, 셀루로즈 아세테이트 프탈레이트, 에틸셀루로즈 프탈레이트, 히드록시프로필메틸 셀루로즈 석시네이트, 셀루로즈아세테이트 석시네이트 히드록시프로필메틸셀루로즈 헥사하이드로프탈레이트, 셀루로즈 아세테이트 헥사하이드로 프탈레이트, 히드록시프로필메틸셀루로즈 트리멜리테이트, 메타크릴산/메타크릴산 에스테르 공중합체(산가 300 내지 330)로 이루어지거나 서로의 혼합물로 이루어짐이 특징인 방법.
- 제5항에 있어서, 장액에 가용인 랙크가 메타크릴산/메타크릴산 에스테르 공중합체(산가 180 내지 200)50중량%와 히드록시프로필메틸셀루로즈 프탈레이트 50중량%로 구성되어 있음이 특징인 방법.
- 제1항 내지 제4항중의 어느 하나에 있어서, 구형입자가 산 또는 산성물질로된 중심 개시핵을 함유하고 있으며 구형입자를 장액에 가용인 랙크성분으로 입한 다음 그것에 브롬헥신 또는 브롬헥신염을 적용시킴이 특징인 방법.
- 제1항 내지 제7항중의 어느 하나에 있어서, 구형입자를 경질 젤라틴 캅셀에 충진시킴이 특징인 방법.
- 제1항 내지 제7항중의 어느 하나에 있어서, 1.5mm 까지의 직경을 가진 구형입자를 통상의 부형제와 함께 압축타정하여 정제를 정조함이 특징인 방법.
- 제1항 내지 제7항중의 어느 하나에 있어서, 산성 작용을 가진 다른 물질을 개시핵에 또한 사용할 수 있고 적용시킬 혼합들에 사용함이 특징인 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP3126703.3 | 1981-07-07 | ||
DE19813126703 DE3126703A1 (de) | 1981-07-07 | 1981-07-07 | Bromhexin-retardform und verfahren zu ihrer herstellung |
Publications (2)
Publication Number | Publication Date |
---|---|
KR840000230A true KR840000230A (ko) | 1984-02-18 |
KR880001753B1 KR880001753B1 (ko) | 1988-09-12 |
Family
ID=6136275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR8203017A KR880001753B1 (ko) | 1981-07-07 | 1982-07-06 | 브롬헥신 서방출성 제형의 제조방법 |
Country Status (24)
Country | Link |
---|---|
US (1) | US4438091A (ko) |
EP (1) | EP0069259B1 (ko) |
JP (1) | JPS5859916A (ko) |
KR (1) | KR880001753B1 (ko) |
AR (1) | AR229183A1 (ko) |
AT (1) | ATE11106T1 (ko) |
AU (1) | AU556917B2 (ko) |
CA (1) | CA1205384A (ko) |
CS (1) | CS244909B2 (ko) |
DE (2) | DE3126703A1 (ko) |
DK (1) | DK163171C (ko) |
ES (1) | ES8400667A1 (ko) |
FI (1) | FI822375L (ko) |
GB (1) | GB2101485B (ko) |
GR (1) | GR76850B (ko) |
HU (1) | HU186538B (ko) |
IE (1) | IE53803B1 (ko) |
IL (1) | IL66224A (ko) |
NO (1) | NO159061C (ko) |
NZ (1) | NZ201182A (ko) |
PH (1) | PH20651A (ko) |
PL (1) | PL142312B1 (ko) |
PT (1) | PT75198B (ko) |
ZA (1) | ZA824786B (ko) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522625A (en) * | 1982-09-29 | 1985-06-11 | Alza Corporation | Drug dispenser comprising wall formed of semipermeable member and enteric member |
DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
AU574360B2 (en) * | 1983-05-13 | 1988-07-07 | Reichert, D. | Antisnoring agent |
DE3317558A1 (de) * | 1983-05-13 | 1984-11-15 | Dietrich Dr.med. Sta. Eulalia Ibiza Reichert | Orales antischnarchmittel |
DE3320582A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
DE3320583A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
JPS6051106A (ja) * | 1983-08-31 | 1985-03-22 | Yamanouchi Pharmaceut Co Ltd | 塩酸アモスラロ−ル持続性製剤 |
IE56459B1 (en) * | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
GB8414220D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
GB8414221D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Unit dosage form |
US4867984A (en) * | 1984-11-06 | 1989-09-19 | Nagin K. Patel | Drug in bead form and process for preparing same |
DE3524003A1 (de) | 1985-07-04 | 1987-01-08 | Heumann Ludwig & Co Gmbh | Arzneimittelgranulat mit verzoegerter wirkstofffreisetzung und verfahren zu seiner herstellung |
GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
JP3426230B2 (ja) * | 1991-05-20 | 2003-07-14 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | 複数層の制御放出処方剤 |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
US5332727A (en) * | 1993-04-29 | 1994-07-26 | Birkmayer U.S.A. | Stable, ingestable and absorbable NADH and NADPH therapeutic compositions |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
JP3149125B2 (ja) * | 1995-05-01 | 2001-03-26 | 信越化学工業株式会社 | 固形腸溶製剤のコーティング用基剤 |
WO2000018396A1 (fr) * | 1998-09-25 | 2000-04-06 | Sankyo Company, Limited | PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA |
JP2000159692A (ja) * | 1998-09-25 | 2000-06-13 | Sankyo Co Ltd | HMG―CoAレダクタ―ゼ阻害薬含有製剤 |
US6319332B1 (en) | 1999-06-11 | 2001-11-20 | James Albert Gavney, Jr. | Squeegee device and system |
JP2003508422A (ja) | 1999-09-02 | 2003-03-04 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | 放出制御ペレット製剤 |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
PL210862B1 (pl) * | 2002-03-07 | 2012-03-30 | Boehringer Ingelheim Pharma | Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji |
DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
DE10341414A1 (de) * | 2003-09-05 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe |
DE102004023930A1 (de) * | 2004-05-12 | 2005-12-08 | Boehringer Ingelheim Vetmedica Gmbh | Schnell lösliches Granulat von Bromhexin/Bromhexinhydrochlorid, Verfahren zu dessen Herstellung und dessen Verwendung |
AU2006226293B2 (en) | 2005-03-22 | 2011-04-07 | Losan Pharma Gmbh | Solubilized ibuprofen |
JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
CN103211779B (zh) * | 2006-01-27 | 2016-03-16 | 阿代尔制药股份有限公司 | 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统 |
ES2533563T5 (es) * | 2006-01-27 | 2018-07-24 | Adare Pharmaceuticals, Inc. | Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos |
DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
US20080181932A1 (en) * | 2007-01-30 | 2008-07-31 | Drugtech Corporation | Compositions for oral delivery of pharmaceuticals |
US8679541B2 (en) * | 2007-03-14 | 2014-03-25 | Particle Dynamics International, Llc | Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals |
PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
WO2009085306A1 (en) | 2007-12-28 | 2009-07-09 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
RU2520801C2 (ru) | 2009-12-11 | 2014-06-27 | ТАЙКО ХЕЛСКЕА ГРУП эЛПи | Устройство для съема материала с улучшенной эффективностью захвата и способы применения |
EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
CN105640909B (zh) | 2014-11-14 | 2019-09-20 | 正大天晴药业集团股份有限公司 | 一种含有达比加群酯的药用组合物 |
US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2971889A (en) | 1958-03-18 | 1961-02-14 | Smith Kline French Lab | Press coated enteric tablets and process for preparing them |
US2928770A (en) | 1958-11-28 | 1960-03-15 | Frank M Bardani | Sustained action pill |
BE625022A (ko) * | 1961-11-20 | 1900-01-01 | ||
US3247066A (en) | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
NL297631A (ko) | 1963-06-03 | |||
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
DE2031871C3 (de) | 1970-06-27 | 1974-06-27 | Roehm Gmbh, 6100 Darmstadt | Überzugsmasse für Arzneiformen |
CA952431A (en) * | 1970-09-28 | 1974-08-06 | Frank M. Bardani | Controlled release medicament |
GB1468172A (en) | 1973-03-28 | 1977-03-23 | Benzon As Alfred | Oral drug preparations |
DE2336218C3 (de) | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
DE2416142A1 (de) * | 1974-04-03 | 1975-10-16 | Thomae Gmbh Dr K | Antiulcus-mittel |
DD146547A5 (de) | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
-
1981
- 1981-07-07 DE DE19813126703 patent/DE3126703A1/de not_active Withdrawn
-
1982
- 1982-06-18 AT AT82105329T patent/ATE11106T1/de not_active IP Right Cessation
- 1982-06-18 DE DE8282105329T patent/DE3261839D1/de not_active Expired
- 1982-06-18 EP EP82105329A patent/EP0069259B1/de not_active Expired
- 1982-06-29 NO NO822216A patent/NO159061C/no unknown
- 1982-06-30 US US06/393,760 patent/US4438091A/en not_active Expired - Fee Related
- 1982-07-01 GR GR68610A patent/GR76850B/el unknown
- 1982-07-05 IL IL66224A patent/IL66224A/xx unknown
- 1982-07-05 AR AR289885A patent/AR229183A1/es active
- 1982-07-05 FI FI822375A patent/FI822375L/fi not_active Application Discontinuation
- 1982-07-06 HU HU822209A patent/HU186538B/hu unknown
- 1982-07-06 DK DK303682A patent/DK163171C/da not_active IP Right Cessation
- 1982-07-06 CA CA000406680A patent/CA1205384A/en not_active Expired
- 1982-07-06 PT PT75198A patent/PT75198B/pt not_active IP Right Cessation
- 1982-07-06 KR KR8203017A patent/KR880001753B1/ko active
- 1982-07-06 NZ NZ201182A patent/NZ201182A/xx unknown
- 1982-07-06 ZA ZA824786A patent/ZA824786B/xx unknown
- 1982-07-06 IE IE1626/82A patent/IE53803B1/en not_active IP Right Cessation
- 1982-07-06 GB GB08219469A patent/GB2101485B/en not_active Expired
- 1982-07-06 AU AU85646/82A patent/AU556917B2/en not_active Ceased
- 1982-07-06 PL PL1982237305A patent/PL142312B1/pl unknown
- 1982-07-06 JP JP57117656A patent/JPS5859916A/ja active Pending
- 1982-07-06 CS CS825163A patent/CS244909B2/cs unknown
- 1982-07-06 ES ES513754A patent/ES8400667A1/es not_active Expired
- 1982-07-07 PH PH27761A patent/PH20651A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR840000230A (ko) | 브롬헥신 서방출성 제형의 제조방법 | |
KR920005808B1 (ko) | 용해 유체내의 유효성분을 영차 방출하는 서방정 및 이의 제조방법 | |
FI113743B (fi) | Menetelmä säädetysti vapauttavan valmisteen valmistamiseksi | |
KR100280099B1 (ko) | 방출 개시 제어 및 방출 속도 제어형 제제 | |
US6436438B1 (en) | Tramadol multiple unit formulations | |
US4865849A (en) | Tablet for pharmaceutical use able to release active substances at successive times | |
EP0220143B1 (en) | New pharmaceutical preparation with controlled release of metoprolol, a method for the manufacture thereof and the use of the new preparation | |
EP0310814B1 (en) | Novel controlled release formulations of tetracycline compounds | |
US4083949A (en) | New oral form of medicament and a method for producing it | |
US3492397A (en) | Sustained release dosage in the pellet form and process thereof | |
EP0391518B1 (en) | Sustained-release pharmaceutical preparation | |
US5246714A (en) | Drug preparation | |
US4968505A (en) | Long-acting diclofenac sodium preparation | |
US5175003A (en) | Dual mechanism controlled release system for drug dosage forms | |
JPH0643312B2 (ja) | 薬学的調合剤 | |
JPH082782B2 (ja) | 徐放性医薬製剤 | |
JPH0772130B2 (ja) | 持続性製剤 | |
EP0438249A1 (en) | Controlled absorption naproxen formulation for once-daily administration | |
EP0103991A2 (en) | Analgesic capsule | |
PL193899B1 (pl) | Powlekany preparat farmaceutyczny z kontrolowanymuwalnianiem substancji czynnej | |
FI86373B (fi) | Belaeggning foer en farmaceutiskt tablett med foerdroejd effekt och foerfarande foer framstaellning av en tablett. | |
JPS62114910A (ja) | 吸収がコントロ−ルされた医薬製剤 | |
KR970001656B1 (ko) | 조절흡수 딜티아젬 제제 | |
US20060039997A1 (en) | Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration | |
CN101987083A (zh) | 一种控释制剂特别是零级释放的控释制剂制备方法 |